| Item Type | Name |
|
Concept
|
Idiopathic Pulmonary Fibrosis
|
|
Academic Article
|
Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation.
|
|
Academic Article
|
Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study.
|
|
Academic Article
|
Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis.
|
|
Academic Article
|
Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.
|
|
Academic Article
|
Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air.
|
|
Academic Article
|
Use of a Genomic Classifier in Patients with Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
|
|
Academic Article
|
Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
|
|
Academic Article
|
Commensal Oral Microbiota, Disease Severity, and Mortality in Fibrotic Lung Disease.
|
|
Academic Article
|
Open-access biorepository for idiopathic pulmonary fibrosis. The way forward.
|
|
Academic Article
|
Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
|
|
Academic Article
|
Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
A multidimensional classifier to support lung transplant referral in patients with pulmonary fibrosis.
|
|
Academic Article
|
Radiographic Honeycombing and Altered Lung Microbiota in Patients with Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.
|
|
Academic Article
|
Association of circulating cell-free double-stranded DNA and metabolic derangements in idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Sex differences in physiological progression of idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
|
|
Academic Article
|
Reply to Stowasser et?al.: Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good.
|
|
Academic Article
|
Erratum: The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.
|
|
Academic Article
|
Biological Age, Chronological Age, and Survival in Pulmonary Fibrosis: A Causal Mediation Analysis.
|
|
Academic Article
|
The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes.
|
|
Academic Article
|
Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.
|
|
Academic Article
|
Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial).
|
|
Academic Article
|
Pitfalls in developing new compounds for idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
|
|
Academic Article
|
Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.
|
|
Academic Article
|
Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients.
|
|
Academic Article
|
The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Transbronchial Lung Cryobiopsy in Patients with Interstitial Lung Disease: A Systematic Review.
|
|
Academic Article
|
Mitochondrial Dysfunction as a Pathogenic Mediator of Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes.
|
|
Academic Article
|
Acute exacerbations of idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.
|
|
Academic Article
|
Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial.
|
|
Academic Article
|
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report.
|
|
Academic Article
|
Machine Learning of Plasma Proteomics Classifies Diagnosis of Interstitial Lung Disease.
|
|
Academic Article
|
Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Comprehensive and Individualized Patient Care in Idiopathic Pulmonary Fibrosis: Refining Approaches to Diagnosis, Prognosis, and Treatment.
|
|
Academic Article
|
Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE).
|
|
Academic Article
|
Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
|
|
Academic Article
|
Predicting pulmonary fibrosis disease course from past trends in pulmonary function.
|
|
Academic Article
|
Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.
|
|
Academic Article
|
Why Does an Aging Smoker's Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease?
|
|
Academic Article
|
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
|
|
Academic Article
|
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
|
|
Academic Article
|
Predictors of idiopathic pulmonary fibrosis in absence of radiologic honeycombing: A cross sectional analysis in ILD patients undergoing lung tissue sampling.
|
|
Academic Article
|
Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Baseline values and short serial change: a "road map" for a poor early outcome in idiopathic pulmonary fibrosis.
|
|
Academic Article
|
An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
|
|
Academic Article
|
Genome-wide Enrichment of TERT Rare Variants in Idiopathic Pulmonary Fibrosis Patients of Latino Ancestry.
|
|
Academic Article
|
Update in Interstitial Lung Disease 2014.
|
|
Academic Article
|
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Idiopathic Pulmonary Fibrosis: Gender-Age-Physiology Index Stage for Predicting Future Lung Function Decline.
|
|
Academic Article
|
Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
|
|
Academic Article
|
Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.
|
|
Academic Article
|
Acute Myocardial Infarction and Pulmonary Diseases Result in Two Different Degradation Profiles of Elastin as Quantified by Two Novel ELISAs.
|
|
Academic Article
|
PCSK6 and Survival in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study.
|
|
Academic Article
|
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
|
|
Academic Article
|
Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia.
|
|
Academic Article
|
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test.
|
|
Academic Article
|
Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment.
|
|
Academic Article
|
Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF.
|
|
Academic Article
|
Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.
|
|
Academic Article
|
Pharmacogenetics and interstitial lung disease.
|
|
Academic Article
|
TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.
|
|
Academic Article
|
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Gender influences Health-Related Quality of Life in IPF.
|
|
Academic Article
|
Measurement of MMP-9 and -12 degraded elastin (ELM) provides unique information on lung tissue degradation.
|
|
Academic Article
|
A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis.
|
|
Academic Article
|
Rare and Common Variants in KIF15 Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective.
|
|
Academic Article
|
Toll-Interacting Protein and Altered Lung Microbiota in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
|
|
Academic Article
|
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.
|
|
Academic Article
|
Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.
|
|
Academic Article
|
A Phase IIb Randomized Clinical Study of an Anti-av?6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Serum proteomic profiling of rheumatoid arthritis-interstitial lung disease with a comparison to idiopathic pulmonary fibrosis.
|
|
Academic Article
|
CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab.
|
|
Academic Article
|
NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.
|
|
Academic Article
|
Enhanced monocyte chemoattractant protein-3/CC chemokine ligand-7 in usual interstitial pneumonia.
|
|
Academic Article
|
Identification of a unique temporal signature in blood and BAL associated with IPF progression.
|
|
Academic Article
|
Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia.
|
|
Academic Article
|
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema.
|
|
Academic Article
|
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
|
|
Academic Article
|
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis.
|
|
Academic Article
|
Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells.
|
|
Academic Article
|
The natural history of progressive fibrosing interstitial lung diseases.
|
|
Academic Article
|
Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.
|
|
Academic Article
|
Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study.
|
|
Academic Article
|
A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.
|
|
Academic Article
|
Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease.
|
|
Academic Article
|
Reply: Improving Care for Patients with Interstitial Lung Disease, Using Machine Learning, Requires Transparency and Reproducibility.
|
|
Academic Article
|
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
|
|
Academic Article
|
Idiopathic Pulmonary Fibrosis.
|
|
Academic Article
|
Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT in patients with little or no radiological evidence of honeycombing: secondary analysis of a randomised, controlled trial.
|
|
Academic Article
|
A Molecular Classifier That Identifies Usual Interstitial Pneumonia in Transbronchial Biopsy Specimens of Patients With Interstitial Lung Disease.
|
|
Academic Article
|
N-acetylcysteine for idiopathic pulmonary fibrosis: the door is still open.
|
|
Academic Article
|
The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis.
|